Evidence map›Paper›PMID 35541503›Full record

ArticleRSC advances2018

Bicyclo[2.2.1]heptane containing

Jin-Xin Che, Zhi-Long Wang, Xiao-Wu Dong, You-Hong Hu, Xin Xie, Yong-Zhou Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Discovery of 1,5-Dihydro-4ACS medicinal chemistry letters · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jin-Xin CheZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University Hangzhou PR China huyz@zju.edu.cn.
Zhi-Long WangState Key Laborarory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai PR China.
Xiao-Wu DongZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University Hangzhou PR China huyz@zju.edu.cn.ORCID https://orcid.org/0000-0002-2178-4372
You-Hong HuState Key Laborarory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai PR China.ORCID https://orcid.org/0000-0002-6180-9183
Xin XieState Key Laborarory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai PR China.
Yong-Zhou HuZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University Hangzhou PR China huyz@zju.edu.cn.ORCID https://orcid.org/0000-0001-7202-9214

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CXCR1 and CXCR2 are CXC chemokine receptors (CXCRs), corresponding to cytokines of the CXC chemokine family. CXCR2 was found to be 77% homologous to CXCR1. Antagonism of the chemokine receptor CXCR2 has been proposed as a new strategy for the treatment of metastatic cancer. In order to find a CXCR2 selective antagonist, a bicyclo[2.2.1]heptane containing

Identifiers

PMID35541503
PMCPMC9078949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.